Purchase Order 75N98026P01064

<p>The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Oxford Nanopore Technologies Inc. for $83,900.00 on July 10, 2026, for PromethION flow cell packs (DNA and RNA volumes) on a firm fixed price basis.</p> <p>Performance occurs in New York, New York. The order is not set-aside. Ultimate completion is scheduled for July 9, 2027.</p>

The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Human Metabolome Technologies America, Inc. for $17,000.00 on June 18, 2026, with final completion by June 17, 2027. The order is firm fixed price with no set-aside category. Performance occurs in Boston, Massachusetts. The National Institute on Alcohol Abuse and Alcoholism conducts studies to determine the contribution of genetics and metabolomics in the etiology of substance abuse disorders through the...

<p>The National Institute on Alcohol Abuse and Alcoholism awarded a purchase order to Illumina, Inc. on July 8, 2026 for an Infinium Global Diversity Array-8 V1.0 kit (96 samples) with a total value of $24,031.45 on a firm fixed-price basis. Place of performance is Bethesda, Maryland. The order is not set-aside. Ultimate completion is July 7, 2027.</p>

<p>The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a purchase order to Reprocell U.S.A., Inc. on July 10, 2026, for 124 PAXgene tubes, with a ceiling value of $32,266.00 under firm fixed pricing. Performance occurs in Calverton, Maryland, with an ultimate completion date of July 9, 2027. No set-aside applies to this commercial item procurement.</p>

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), awarded a $17,380 purchase order to Oxford Nanopore Technologies Inc. for CAS9 sequencing kits. The firm fixed price order is for delivery of the requested products between July 24 and August 4, 2023. Oxford Nanopore Technologies Inc. will perform as the prime contractor, with all work taking place in New York, NY....

The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health within the Department of Health and Human Services, has awarded a firm fixed price purchase order valued at $18,302.40 to Life Technologies Corporation. Under this contract, Life Technologies will provide NIAAA with supplies consisting of an 8-plex mouse proteome panel to support alcohol-related research efforts. Performance will take place in Grand Island, New York over a one...

<p>The National Institute on Alcohol Abuse and Alcoholism issued a delivery order to Illumina, Inc. on August 28, 2017, with a ceiling value of $9,819.42 for an Infinium OmniExpressExome 8 sequencing kit.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with an ultimate completion date of September 2, 2020. No set-aside was used.</p>

<p>The National Institute on Alcohol Abuse and Alcoholism issued a $25,459.20 delivery order to Illumina, Inc. on August 7, 2019, for genetic sequencing equipment and related genomic analysis technologies.</p> <p>Place of performance is Bethesda, Maryland. The order has a firm fixed price and an ultimate completion date of September 2, 2020. No set-aside was used.</p>

<p>The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a purchase order to Illumina, Inc. for $119,641.00 on December 1, 2022, for preventative maintenance of Tecan LIHA equipment under a firm fixed-price contract with a ceiling through November 30, 2027.</p> <p>Work is performed in North Bethesda, Maryland. The order includes a base period and four option years. No small business set-aside applies.</p>

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $90.1K firm fixed-price purchase order to Oxford Nanopore Technologies Inc. for a PromethION 2 integrated sequencing unit and related support services. This severable purchase order (ONT-077966) was awarded on July 18, 2025, with an ultimate completion date of July 17, 2026, and will be performed in New York, NY. The award includes no set-aside designation and represents a direct procurement of advanced genomic sequencing...